In January 2008, the Clinical and Laboratory Standards Institute published revised susceptibility breakpoints for penicillin and Streptococcus pneumoniae, and shortly thereafter, the United States Food and Drug Administration similarly revised its breakpoints via changes in the package insert for penicillin. The revised susceptibility breakpoint is р2 mg/mL for nonmeningeal infections treated with parenteral penicillin at a dosage of 12 million units-24 million units per day. The susceptibility breakpoint of р0.06 mg/mL remains unchanged for pneumococcal meningitis treated with parenteral penicillin at a dosage of у18 million units per day. Herein, we review the scientific basis for the revisions to the breakpoints, which were supported by microbiologic, pharmacokinetic and/or pharmacodynamic, and clinical data. Clinicians, once again, should feel comfortable prescribing penicillin for pneumococcal pneumonia and other pneumococcal infections outside the central nervous system.
In January 2008, the Clinical and Laboratory Standards Institute (CLSI) published revised breakpoints for susceptibility when testing penicillin against Streptococcus pneumoniae [1] ; in March 2008, the United States (US) Food and Drug Administration susceptibility breakpoints for penicillin versus S. pneumoniae were similarly revised via changes in the penicillin package insert for the primary generic manufacturer. The revised breakpoints for infection other than meningitis are: susceptible, р2 mg/mL; intermediate, 4 mg/mL; and resistant, у8 mg/mL (table 1) . For meningitis, the breakpoints are: susceptible, р0.06 mg/mL; and resistant, у0.12 mg/mL. This article provides the background and rationale for these changes and summarizes the relevant microbiologic, pharmacokinetic and/ or pharmacodynamic, and clinical information that led to the decision to revise the breakpoints.
Prior to the recent revisions, penicillin breakpoints for pneumococci, derived in the late 1970s, were predicated on the need to assure the success of therapy for pneumococcal meningitis.
Because penicillin minimum inhibitory concentrations (MICs) began to increase in subsequent decades and more pneumococcal isolates were reported as intermediate or resistant to penicillin (table 1) , many clinicians abandoned the use of penicillin for both empirical and culture-directed therapy for community-acquired pneumonia in favor of newer, broader-spectrum, more expensive antimicrobials. However, retrospective [2] and prospective [3] studies involving adults, as well as studies involving children [4] , demonstrated that the outcomes of pneumococcal pneumonia caused by penicillin-nonsusceptible strains were no different in patients treated with parenteral penicillin than in patients treated with other agents, suggesting that the susceptibility breakpoint established for meningitis (р0.06 mg/mL) did not apply to pneumonia. Over time, other investigators confirmed these findings in large observational multicenter studies [5, 6] . These results, as well as a review and reassessment of the microbiologic and pharmacokinetic and/ or pharmacodynamic data that supported the concept of breakpoint revisions for pneumococcal infections other than meningitis, led the CLSI Subcommittee on Antimicrobial Susceptibility Testing to establish a Working Group to reconsider the penicillin breakpoints for S. pneumoniae.
CLSI DATA REVIEW PROCESS
In setting or reconsidering susceptibility breakpoints, CLSI reviews 3 types of data: microbiologic, pharmacokinetic and/or pharmacodynamic, and clinical outcome [7] . The microbiologic data include MIC distributions of the relevant drug against clinical isolates from broad geographic origins, strains with known drug resistance mechanisms, analysis of cross-susceptibility or resistance with other relevant antimicrobials (e.g., penicillins and cephalosporins), and correlation of results obtained with different testing methods (e.g., disk diffusion vs. broth dilution). Pharmacokinetic and/or pharmacodynamic data include pharmacokinetic profiles of the drug in serum and/or plasma, the percentage of protein binding of the drug, and information linking drug exposure to killing of the organisms observed in vitro or in animal models. Clinical outcome data for new drugs usually come from controlled clinical trials. However, in the case of an older agent such as penicillin, data must be collected from a variety of sources and include dosage used, frequency of administration, and a measure of clinical response stratified by the MICs of the organisms recovered.
MICROBIOLOGIC DATA
The microbiologic impact of changing the parenteral penicillin susceptibility breakpoint was assessed using results from recent (through 2006) antimicrobial resistance surveillance programs that applied CLSI reference broth microdilution methods [8, 9] . Table 2 from the SENTRY Antimicrobial Surveillance Program (R.N.J., unpublished observations) illustrates the cumulative percentages of S. pneumoniae isolates worldwide that are inhibited by penicillin and selected parenteral (cefepime, cefotaxime, ceftriaxone, and ceftazidime) and orally administered (amoxicillin-clavulanate) b-lactams. With a penicillin susceptibility breakpoint of р0.06 mg/mL, only 68% of isolates are susceptible to penicillin; in contrast, with a breakpoint of р2 mg/mL, 93% of isolates are susceptible. With the new nonmeningitis breakpoint, the proportion of isolates susceptible to penicillin is comparable with the proportion of isolates susceptible to other b-lactams at their nonmeningitis breakpoints [1] : cefepime (95%), cefotaxime (97%), and ceftriaxone (96%). At the р2/1 mg/mL breakpoint for amoxicillin-clavulanate [1] , the oral b-lactamase inhibitor combination had coverage (92%) nearly equal to that of penicillin, whereas ceftazidime (which has no CLSI breakpoint) was 4-to 8- surveillance networks, the perceived clinical utility of parenteral penicillin would increase ∼25% with a revised susceptibility breakpoint of р2 mg/mL for nonmeningitis infections. When the nonmeningitis breakpoint modifications for cefepime, cefotaxime, and ceftriaxone were published by the CLSI in 2002, increases in susceptibility rates also were observed-for example, absolute increases of 9.1%-13.0% [10] .
Cross-susceptibility and cross-resistance analyses were performed using SENTRY Program data from 1997 through 2007 (р31,225 isolates). Table 2 shows a detailed comparison of penicillin (breakpoints, р0.06 and р2 mg/mL) with other blactams, and table 3 shows a comparison with ceftriaxone (nonmeningitis breakpoint, р1 mg/mL) [1] . Table 4 shows error rates if penicillin at a breakpoint of р2 mg/mL is used to predict the susceptibility of S. pneumoniae to other b-lactams. (table 4) . Similar analyses were done using the oral nonmeningitis penicillin (penicillin VK) and the meningitis penicillin (penicillin G at a dosage of 3 million units [MU] every 4 hours) breakpoint of р0.06 mg/mL. At this breakpoint, susceptibility to penicillin was an excellent predictor of susceptibility (not resistance) to the following oral agents: amoxicillin-clavulanate, cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime, and loracarbef. The 10-unit penicillin disk diffusion test has limited accuracy against pneumococci, and the oxacillin disk (1 mg) screening test continues to be recommended to predict penicillin MICs of р0.06 mg/mL [1, 11] . Furthermore, disk diffusion tests for cefepime, cefotaxime, and ceftriaxone are not recommended in the CLSI documents [1] , which favor the application of reference MIC methods.
PHARMACOKINETIC AND/OR PHARMACODYNAMIC DATA
Penicillin, like other cell wall-active agents, exhibits time-dependent killing. Thus, for therapeutic success, it is necessary to attain drug concentrations that exceed the MIC of the infecting microorganism at the site of infection for a critical period. Published results [12] [13] [14] [15] and table 5 (P. Ambrose, personal communication) provide evidence that in the case of penicillins, the MIC should be exceeded for у25% of the dosing interval. Because penicillin penetrates relatively poorly into cerebrospinal fluid, only pneumococcal isolates with lower MICs will be inhibited for у25% of the dosing interval. By contrast, higher penicillin levels are achieved in body fluids outside the central nervous system, and isolates with higher MICs may be inhibited. During the CLSI Subcommittee's reassessment of the penicillin breakpoints, pharmacokinetic and/ or pharmacodynamic data from potential penicillin simulations were presented that showed that intravenous infusions of 2 MU every 4 hours or 4 MU every 6 hours would support a susceptibility MIC of р2 mg/mL for infections other than meningitis (table 5). In the example shown in table 5, a penicillin G dosage of 2 MU given intravenously every 4 hours would have a 99% likelihood of achieving serum concentrations greater than the MIC for у25% of the interval between doses when treating an isolate with an MIC of 2 mg/mL but only an 81% likelihood of achieving this target when treating an isolate with an MIC of 4 mg/mL. In fact, serum penicillin concentrations greater than the MIC for у30% of the interval between doses (a more conservative calculation) also were achieved by recommended penicillin G dosages. Dosages of penicillin at !12 MU per day could not be used, and dosages of 24 MU per day may be necessary to inhibit S. pneumoniae strains at 4 mg/mL (table 5) . For oral penicillin V at a dosage of 250 mg every 8 hours, experimental models support a susceptibility MIC of р0.06 mg/mL [15] .
CLINICAL DATA
Penicillin-resistant pneumococcal pneumonia is more common in patients with increased risk for mortality, such as those with comorbidities. These risks must be considered to be confounders when therapies for infection caused by pneumococci with elevated MICs are compared with therapies for infection caused by more-susceptible strains. A recent meta-analysis that suggested increased risk for mortality associated with penicillinresistant pneumococcal infection found no difference in the outcome in patients with penicillin-resistant pneumococcal disease treated concordantly (susceptible at the former MIC of р0.06 mg/mL for all strains), compared with those treated discordantly, suggesting that the increase in mortality was associated with factors other than discordance (not susceptible at an MIC of р0.06 mg/mL) of therapy [16, 17] . To investigate the breakpoint at which penicillin monotherapy might fail, a search was made for patients who received penicillin monotherapy for at least the first 48 hours and from whom a pneumococcus strain resistant to penicillin at an MIC у2 mg/mL had been isolated. Data were found in 4 publications. Nineteen patients with pneumococcal pneumonia, all treated in Asian countries, were identified from Song et al. [5] ; 1 patient treated in Sweden was reported from the global study by Yu et al. [6] ; and 7 patients, all of whom had been treated with penicillin alone, were reported in a study in Spain by Palleres et al. [3] . The Spanish article included 3 patients described in an earlier report from the same group [2] . In the Asian study, all consecutive patients (age, у18 years) with community-acquired pneumococcal pneumonia that was diagnosed from January 2000 through June 2001 were prospectively enrolled at 9 study centers. Patients were enrolled only if all of the following findings were present: clinical symptoms and signs of pneumonia (e.g., fever, cough, or sputum), a distinct pulmonary infiltrate on a chest radiograph, and isolation of S. pneumoniae from sterile specimens (blood or pleural fluid) and/or from lower respiratory tract specimens with compatible Gram stain findings. Bacteremia was documented in 72 (30.9%) of the 233 patients, and one-third (80 [34.3%]) of the patients were from Hong Kong. The global study included 844 consecutive hospitalized adults who had received a diagnosis of pneumococcal bacteremia from December 1998 through January 2001, and the Spanish studies included patients with pneumococcal bacteremia diagnosed from January 1981 through September 1986 and from January 1984 through December 1993. Susceptibility testing was performed by reference CLSI methods at central laboratories in the Asian study, by E test method in the global studies, by agar dilution methods in the 1987 Spanish study [2] , and by broth microdilution methods in the 1995 Spanish study [3] . Mortality was assessed at 30 days in the Asian and Spanish studies and at 14 days in the global study. Although dosages of penicillin were not specified, the usual dosage of parenteral penicillin at the sites in Asia for treatment of bacteremic pneumonia was 10 MU-20 MU per day. The case from Sweden was treated with 12 MU per day, which was also the usual dosage of treatment in the Spanish studies.
Of the 27 patients treated with penicillin alone, 5 died (2 of whom were in critical condition at enrollment). The overall survival rate was 81% (22 of 27 patients). The survival rate was 78% (14 of 18 patients) among patients infected with a strain with an MIC of 2 mg/mL, 88% (7 of 8 patients) among those who had an infecting strain with an MIC of 4 mg/mL, and 100% (1 of 1 patient) for the patient who had an infecting strain with an MIC of 8 mg/mL. These data suggest that there is no relationship between mortality and penicillin MIC у2 mg/mL when patients receive penicillin monotherapy at a dosage of у10 MU per day (usually у12 MU per day).
CONCLUSIONS
Taken together, the data support a revised penicillin susceptibility breakpoint of р2 mg/mL for pneumococcal infection outside the central nervous system. On the basis of contemporary microbiologic data, 90%-95% of all S. pneumoniae strains will have MIC results in the susceptible range. By allowing the revision to the penicillin package insert, the Food and Drug Administration concurred with the CLSI Subcommittee on Antimicrobial Susceptibility Testing. Clinicians, once again, should feel comfortable prescribing parenteral penicillin for pneumococcal pneumonia and other pneumococcal infection outside the central nervous system.
For the reporting of penicillin resistance in epidemiologic surveillance studies, it may be useful to continue to report data by means of both the meningitis (р0.06 mg/mL) and nonmeningitis (р2 mg/mL) breakpoints-the former to allow an assessment of penicillin susceptibility for treating meningitis but also to allow for continuity in the reporting of long-term resistance occurrence data and the latter to encourage the appropriate use of parenteral penicillin for pneumococcal pneumonia for which susceptibility at the new nonmeningitis breakpoint remains high.
